Veradermics (NYSE:MANE) Stock Price Expected to Rise, Citigroup Analyst Says

Key Points

• Citigroup raised its price target on Veradermics to $175 from $160 and maintained a Buy rating, implying 17.67% upside from the share price cited. Analysts’ consensus target is $174.57, with an overall Moderate Buy rating.
• Veradermics reported positive 12-month results from Part B of its Phase 3 Study 302, including the highest hair-count result so far in its VDPHL01 Phase 3 program. The company also reported a third-quarter loss of $0.50 per share.
• Insiders sold 961,000 shares worth about $103.1 million over the past 90 days, according to the report.

Veradermics (NYSE:MANE - Get Free Report) had its price objective raised by Citigroup from $160.00 to $175.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the stock. Citigroup's price target indicates a potential upside of 17.67% from the stock's current price.

A number of other equities research analysts have also recently commented on MANE. Wall Street Zen raised shares of Veradermics from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Cantor Fitzgerald reissued an "overweight" rating on shares of Veradermics in a report on Monday, October 19th. UBS Group set a $204.00 price target on Veradermics in a research report on Thursday, October 22nd. Leerink Partners upped their price objective on Veradermics from $135.00 to $150.00 and gave the company an "outperform" rating in a research note on Monday. Finally, B. Riley Financial increased their price objective on Veradermics from $170.00 to $204.00 and gave the stock a "buy" rating in a research report on Thursday, October 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $174.57.

Veradermics Price Performance

Shares of MANE traded up $4.76 during mid-day trading on Tuesday, reaching $148.72. 360,002 shares of the company's stock were exchanged, compared to its average volume of 640,036. The business's fifty day simple moving average is $118.66 and its 200-day simple moving average is $97.43. The stock has a market capitalization of $6.21 billion and a PE ratio of -78.29. Veradermics has a 52-week low of $32.00 and a 52-week high of $152.82.

Veradermics (NYSE:MANE - Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.50) EPS for the quarter. Equities research analysts predict that Veradermics will post -2.87 earnings per share for the current year.

Insider Activity

In other news, Director John Childs sold 100,000 shares of the firm's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $107.12, for a total value of $10,712,000.00. Following the completion of the sale, the director owned 194,117 shares in the company, valued at approximately $20,793,813.04. This trade represents a 34.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Montanova Capital, Llc sold 750,000 shares of the firm's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $107.25, for a total transaction of $80,437,500.00. Following the completion of the sale, the director owned 461,033 shares of the company's stock, valued at $49,445,789.25. This trade represents a 61.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 961,000 shares of company stock worth $103,120,220 in the last 90 days.

Institutional Investors Weigh In On Veradermics

A number of institutional investors have recently added to or reduced their stakes in MANE. Nvwm LLC grew its holdings in Veradermics by 105.4% during the third quarter. Nvwm LLC now owns 228 shares of the company's stock worth $28,000 after acquiring an additional 117 shares during the period. Sterling Capital Management LLC raised its position in Veradermics by 233.2% in the third quarter. Sterling Capital Management LLC now owns 633 shares of the company's stock worth $77,000 after acquiring an additional 443 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Veradermics by 8.4% in the third quarter. Russell Investments Group Ltd. now owns 1,905 shares of the company's stock valued at $231,000 after acquiring an additional 147 shares during the period. Pictet Asset Management Holding SA lifted its holdings in Veradermics by 22.0% in the third quarter. Pictet Asset Management Holding SA now owns 2,491 shares of the company's stock valued at $302,000 after acquiring an additional 449 shares during the period. Finally, Arizona State Retirement System purchased a new stake in shares of Veradermics during the 2nd quarter worth $524,000.

Key Veradermics News

Here are the key news stories impacting Veradermics this week:

• Positive Sentiment: Veradermics reported positive 12-month results from Part B of Phase 3 Study 302 in men with pattern hair loss, including the highest hair-count result reported in its VDPHL01 Phase 3 program to date. The clinical progress may strengthen the candidate’s commercial prospects. Article: Veradermics Achieved the Highest VDPHL01 Reported Hair Count
• Positive Sentiment: Leerink Partners raised its price target from $135 to $150 and maintained an Outperform rating, signaling continued analyst optimism, though the revised target implies limited upside relative to the price cited in the report. Analyst rating information
• Neutral Sentiment: Veradermics reported a third-quarter 2026 loss of $0.50 per share. The available report does not provide an analyst-consensus comparison, making the earnings result’s surprise impact unclear. Article: Veradermics Reports Third Quarter 2026 Results

Veradermics Company Profile

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.